ARCHIVES

Contract Proposal Would Assess Outcomes Other Than Incidence, Response, Mortality

This article is from The Cancer Letter archive.

Vol. 13 No. 36 | September 18, 1987

Download PDF Visit The Full Archive

Related Articles

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

August 30, 2013

Chabner Calls For Audit Of I-ELCAP Data, Full Financial Disclosure.

May 2, 2008

NCI-Approved Clinical Trials For The Month of June

June 24, 2011

Benefit Seen In Novel Drug That Treats Gleevec Resistance

April 29, 2005

In Brief: New San Antonio Center Wins Core Grants; ASCO forming A Technology Assessment Committee

July 19, 1991

DRG Regulation Opponents May Have Powerful New Ally

November 25, 1983